九个关于增强治疗α-1抗素缺乏症的有争议的问题:一个观点
Marc Miravitlles1, Antonio Anzueto2, Miriam Barrecheguren3
1Pneumology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain marcm@separ.es.
概括
静脉输入的α-1抗素增强疗法是治疗与α-1抗素缺乏症 (AATD) 相关的肺瘤的唯一方法. 由于疾病的罕见性和异质性,其长期使用引发了关于最佳使用,有效性和患者选择的问题.
科学领域:
- 肺部病理学 肺部病理学
- 罕见疾病 罕见疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 静脉注射α-1抗素 (AAT) 的增强疗法是唯一针对α-1抗素缺乏症 (AATD) 相关的特异性治疗方法.
- 尽管它已存在超过35年,但关于其适用,使用和有效性仍然存在重大不确定性.
研究的目的:
- 为了解决围绕AAT增强疗法治疗AATD相关的肺瘤的持久问题和辩论.
- 探索临床试验设计和罕见疾病 (如AATD) 的结果测量方面的挑战.
- 讨论个性化治疗指示,考虑到疾病异质性和预后.
主要方法:
- 关于AAT增强疗法的现有文献和临床实践的审查.
- 讨论对罕见疾病进行随机对照试验的挑战.
- 分析其他结果测量方法,如肺密度计.
主要成果:
- 缺乏充足的随机对照试验,用于AATD的标准COPD结果.
- 肺密度计是一种敏感的测量方法,但监管机构并不普遍接受.
- 在AATD中,临床表现和疾病进展高度异质,使预后预测复杂化.
结论:
- 对AAT增强疗法的指示需要在专家中心进行个性化决策.
- 关于非肺瘤呼吸道疾病和肺移植后增加的争论仍在继续.
- 在个性化治疗计划中,对增强的优缺点进行知情的患者讨论至关重要.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
229
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
229
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
170
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
170
Myasthenia Gravis: Overview and Treatment
1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Cystic Fibrosis: Management
172
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
172
Pulmonary Tuberculosis I
244
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
244
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
188
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
188


